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Introduction
In patients with polyarticular course of juvenile idiopathic
arthritis (JIA) both, ongoing chronic inflammation with
high levels of pro-inflammatory cytokines and corticoster-
oid treatment, may affect linear growth adversely, poten-
tially leading to irreversible growth retardation. Biologic
treatment of JIA may have the potential to enable normal
growth in children with JIA.
Objectives
To retrospectively evaluate clinical efficacy, from perspec-
tive of growth velocity as a sensitive marker of well-being
in children, of biologics in children with JIA in both
centers in Slovakia.
Methods
34 patients (17 girls, 17 boys) with DMARDs-resistant
polyarticular JIA receiving TNFa blocker (28 etanercept,
6 adalimumab) + methotrexate were evaluated during
their first year of biologic therapy. The mean age at anti-
TNF treatment initiation was 10.52 (range 2.98-17.77).
Median duration of disease was 4.42 years (range 0.89-
10.63), 24 patients received corticosteroids. Control group,
consisted of 21 patients (12 boys, 9 girls) with polyarticular
course of JIA non-responsive to NSAIDs therapy and
intraarticular corticosteroid injections, was evaluated
during their first year of DMARDs treatment. Same inclu-
sion and exclusion criteria, e.g. age and Tanner staging,
were applied for both groups. Growth velocity was defined
by change of height in standard deviation score (SDS). A
positive value >0.1 indicated catch-up and negative value
<-0.1 indicated impaired growth. Values in the range
-0.1 to 0.1 were labeled as “steady growth”.
Results
Efficacy of combination TNFa blocker + MTX treatment
evaluated by ACR Pediatric 30 is increasing during the
first year. In time of year control 34/31/25 patients reach
criteria at least for ACR Pediatric 30/50/70 respectively.
The number of joints with acute arthritis decreased by
91.9 % (from 309 to 25) compared to 91.33 % (from 173 to
15) in control group. TNFa blocker + MTX combination
also shows a rapid corticosteroid-sparing effect. Only 4
patients received corticosteroids at the start of DMARDs
treatment in control group. Clinical response in TNFa
blocker + MTX group was accompanied by catch-up in 18
patients, “steady growth” and impaired growth were
observed in 8 cases both. Clinical response in control
group was accompanied by catch-up only in 3 cases,
“steady growth” and impaired growth were observed in
6 and 8 patients respectively. The difference in growth
velocity was statistically significant (0.106 ± SD 0.439 vs.
-0.139 ± SD 0.385, t = 2.101 df = 53, p = 0.040).
Conclusion
Combination of TNFa blocker + methotrexate is highly
effective in polyarticular course of DMARDs-resistant
JIA. The clinical response is accompanied by an increase
in growth velocity (catch-up) in most cases. The growth
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